11,768 Danaher Corporation $DHR Shares Bought by Adirondack Trust Co.

Adirondack Trust Co. increased its position in Danaher Corporation (NYSE:DHR) by 536.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,963 shares of the conglomerate’s stock after buying an additional 11,768 shares during the quarter. Danaher comprises approximately 1.1% of Adirondack Trust Co.’s holdings, making the stock its 26th largest position. Adirondack Trust Co.’s holdings in Danaher were worth $3,094,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Marquette Asset Management LLC boosted its position in shares of Danaher by 192.1% during the 3rd quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 73 shares in the last quarter. N.E.W. Advisory Services LLC acquired a new stake in Danaher during the second quarter valued at approximately $25,000. Main Street Group LTD bought a new stake in Danaher during the first quarter worth approximately $25,000. Field & Main Bank bought a new stake in Danaher during the second quarter worth approximately $29,000. Finally, Evolution Wealth Management Inc. boosted its holdings in Danaher by 208.0% during the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock worth $29,000 after buying an additional 104 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced a collaboration combining Danaher’s scientific instruments, laboratory workflows, automation technologies and data with NVIDIA’s accelerated computing and AI capabilities. The companies aim to advance autonomous science and speed up research, potentially creating new growth opportunities in life-science tools. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is reportedly preparing to launch its first AI-powered autonomous laboratory, expected to operate at commercial scale in early 2027. The initiative could support demand for Danaher’s instruments, software and laboratory automation offerings as AI adoption expands. How to Invest in AI Drug Discovery
• Positive Sentiment: Zacks said Danaher has two indicators associated with a potential earnings beat ahead of its upcoming report. A stronger-than-expected result could reinforce investor confidence following the company’s previous quarterly beat on revenue and earnings. Danaher Earnings Expected to Grow
• Positive Sentiment: Morgan Stanley maintained its $240 price target for DHR, signaling continued confidence in the stock’s outlook and leaving room for further appreciation based on the referenced trading level. Morgan Stanley Keeps $240 Target for Danaher
• Neutral Sentiment: Danaher appointed Daniel L. Comas and Robert Hershberg to its board, expanding it to 13 members. The appointments may strengthen governance and industry expertise but are unlikely to materially affect near-term trading. Danaher Announces Board Appointments

Wall Street Analysts Forecast Growth

DHR has been the topic of several research reports. Stifel Nicolaus dropped their price target on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Royal Bank Of Canada raised their price objective on Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research note on Monday, October 5th. Guggenheim lifted their target price on Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Wells Fargo & Company cut their target price on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 22nd. Finally, UBS Group began coverage on Danaher in a research report on Wednesday, September 9th. They set a “buy” rating and a $250.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Trading Up 0.6%

Shares of Danaher stock traded up $1.44 during trading on Wednesday, hitting $224.28. The stock had a trading volume of 1,890,805 shares, compared to its average volume of 4,448,106. The stock has a 50 day simple moving average of $212.41 and a 200 day simple moving average of $195.13. The company has a market capitalization of $157.66 billion, a PE ratio of 39.79, a P/E/G ratio of 2.78 and a beta of 0.76. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter in the prior year, the firm earned $0.77 EPS. The firm’s quarterly revenue was up 5.5% on a year-over-year basis. On average, research analysts expect that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s payout ratio is currently 28.42%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.